Dan Liu

4/3/2025 9:34:23 PM

The Landscape of Regeneron’s Eylea® Litigation—Update 1: the Federal Circuit Affirmed the District Court’s Decisions in Celltrion and Amgen

By Dan Liu

After the Federal Circuit’s January decisions1 affirming the preliminary injunction orders that bar Samsung Bioepis (SB) and Formycon...

2/19/2025 6:32:40 PM

By Dan Liu

A biosimilar is a biologic drug that is highly similar, but not identical, to an already approved biologic drug, i.e. the reference...

5/14/2024 10:10:17 PM

By Dan Liu

mRNA-Based Vaccine and Other Therapeutics mRNA-based vaccines have become one of the most discussed technologies both inside and outside...

4/25/2024 9:24:10 PM

By Dan Liu

The district court in Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc., Civil Action No. 20-430-RGA (D. Del.) was asked...

3/9/2024 1:20:28 AM

By Dan Liu

The Biologics Price Competition and Innovation Act (“BPCIA”) created an abbreviated pathway for the licensure of biosimilar and...